To elicit sodium currents the voltage was changed to -120 mV for a period of 50 msec before a test pulse to -20 mV of 20 msec duration. These voltage protocols were repeated at a rate of 0.1 Hz throughout the experiment. A single concentration of test compound was applied to cells for 3-5 minutes. Peak sodium current was measured at the end of the compound addition period to determine percent inhibition. Cells were used for additional compound testing if currents recovered to >80% of starting values following compound washout. At least three different concentrations of test compound at half log units were applied individually, with washout, recovery of current, and resetting of holding voltage between each individual concentration. Percent inhibition as a function of compound concentration was and fit with a Hill (4-parameter logistic) fit in DataXpress 2.0 software to produce a single IC 50 curve.
acclimate to the animal facility for 1 week prior to the start of the experiment. On the day of testing, animals were orally administered either Compound 14 (30, 100, or 300 mg/kg body weight) or a vehicle control formulation (30% Hydroxypropyl beta-cyclodetrin, 70% H 2 O, pH10) between the hours of 7:00 a.m. and 5:00 p.m. Four hours following test article treatment, animals were placed into dimly-lit (15) (16) (17) (18) (19) (20) open-field chambers (16" x 16", Kinder Scientific, San Diego, CA) and behaviour was monitored over a 30-minute period during which horizontal movement parameters were measured in an automated manner via infrared photo beam breaks. Data was analysed statistically via GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA) using a one-way ANOVA to assess the overall test article treatment effect and followed by Dunnett's multiple comparison post-hoc tests. The results of this study are shown in Figure S1 . 
General Chemistry Procedures, Materials, and Instrumentation
Commercial reagents and solvents were used as received. Microwave-assisted reactions were conducted with a Biotage Initiator. NMR spectra were recorded at ambient temperature on a Bruker AV-400 400 MHz spectrometer, a Bruker AV III 500 MHz spectrometer, or a Bruker Advance III spectrometer, operating at a proton frequency of 500 MHz using a Protasis CapNMR flow-probe, equipped with Discovery Tower™ Sample management system and a Waters Liquid Handler, made by CTC, Switzerland (Model 2777). Data are reported in parts per million (δ), and are calibrated using residual non-deuterated solvent as an internal reference: CDCl 3 , δ 7.26 (CHCl 3 ); DMSO-d 6 , δ 2.50 (d 5 -DMSO). Data for 1 H NMR spectra are reported as follows: chemical shift (multiplicity, coupling constants, integration). Multiplicities are reported as follows: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; br = broad, or combinations thereof. Data for 13 C NMR spectra are reported in parts per million (δ) and are referenced from the central peak of the carbon resonance of the solvent: CDCl 3 , δ 77.00; d 6 -DMSO, δ 39.52.
Purifications were performed using standard column chromatography in glass columns or medium pressure liquid chromatography (MPLC) on a CombiFlash Companion (Teledyne Isco) or a Biotage Isolera with prepacked RediSep or Biotage normal-phase silica gel (35−60 μm) columns and UV detection at 254 nm. Preparative reversed-phase high-performance liquid chromatography (HPLC) and high throughput parallel purification were performed with reversed phase preparative LC/MS: Waters auto-purification system; liquid transfer system: Tecan; drying system: Genevac; preparatory column: Xbridge (19 x 100 mm, C18, 10 μm); flow rate: 40 mL/min; general gradient: 5 -95% B, 0.1% additive in both A and B; 10 min gradient; Mobile Phase A: H 2 O, Mobile Phase B, MeCN; Additive: TFA or NH 4 OH. Chiral method development was performed on an analytical Thar SFC/MS. Preparative chiral separations were performed on Thar SFC Prep 80 or SFC Prep 350 instruments. All final compounds were purified to ≥ 95% purity as determined by HPLC.
Purity (3 min methods only) and reaction analyses were measured using Agilent 1100 Series HPLC systems with UV detection at 254 nm and 215 nm (System A: Agilent Zorbax SB-C18 3.0 x 50 mm, 3.5 micron, 5 to 95% MeCN in H 2 O with 0.1% TFA for 3.6 min at 1.5 mL/min; System B: Waters Xbridge C18, 3 x 50 mm, 3.5 micron, 5 to 95% MeCN in H 2 O with 0.1% formic acid for 3.6 min at 1.5 mL/min.
Exact mass confirmation was performed on an Agilent 1200 series high performance liquid chromatography (HPLC) system (Santa Clara, S2 CA, U.S.) by flow injection analysis, eluting with a binary solvent system A and B (A, H 2 O with 0.1% formic acid; B, MeCN with 0.1% formic acid) under gradient conditions (5-95% B over 3 min) at 0.3 mL/min with MS detection by an Agilent 6510-Q-TOF mass spectrometer (Santa Clara, CA, U.S.).
Optical rotations were measured on a Jasco P-2000 digital polarimeter with a sodium lamp (average of three measurements for each sample) using a 3.5 mm x 100 mm cylindrical glass cell.
Chemistry Experimental Section (R)-N-Benzyl-2-(4-(2-chloro-5-fluorobenzoyl)piperazin-1-yl)-2-phenylacetamide (14).
Step 1:
To a DMF (1.0 L) solution of tert-butyl piperazine-1-carboxylate (3, 100. g, 538 mmol) was added potassium carbonate (80. g, 58 mmol) and methyl 2-bromo-2-phenylacetate (S1, 73.5 g, 320. mmol). The reaction contents were stirred at rt for 12 h. The reaction mixture was then filtered through a bed of celite, and the filtrate was concentrated in vacuo. The material was purified by column chromatography using 60-120 mesh silica gel, eluting with 20% EtOAc in heptane, to obtain tert-butyl 4-(2-methoxy-2-oxo-1-phenylethyl)piperazine-1-carboxylate (S2, 100. g, 299 mmol, 67% yield) as a colourless oil. Step 2:
To a THF (125 mL)/H 2 O (62.5 mL) solution of tert-butyl 4-(2-methoxy-2-oxo-1-phenylethyl)piperazine-1-carboxylate (S2, 25 g, 74.8 mmol, 1.0 equiv) was added lithium hydroxide (8.9 g, 370 mmol). The reaction mixture was stirred at rt for 12 h. The reaction mixture was then concentrated in vacuo. The material was acidified to pH 5 using 0.5 N aq. HCl. The layers were separated, and the aqueous layer was extracted thrice with CH 2 Cl 2 . The organic extracts were combined, dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to provide 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-phenylacetic acid (S3, 20. g, 62 mmol, 84% yield) as a white amorphous solid. Step 3:
To a CH 2 Cl 2 (105 mL) solution of 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-phenylacetic acid (S3, 21 g, 66 mmol) and phenylmethanamine (9.13 g, 85.0 mmol) was added triethylamine (27.4 mL, 197 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 31.3 g, 98 mmol). The reaction mixture was stirred at rt for 12 h. The reaction was diluted with CH 2 Cl 2 (250 mL) and H 2 O (300 mL). The layers were separated, and the organic layer was washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The material was purified by column chromatography using 60-120 mesh silica gel, eluting with 20% EtOAc in hexane, to provide tert-butyl 4-(2-(benzylamino)-2-oxo-1-phenylethyl)piperazine-1-carboxylate (S4, 18 g, 44 mmol, 67% yield) as a white amorphous solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ 7. 47 -7.40 (m, 2H), 7.41 -7.26 (m, 5H), 7.24 -7.20 (m, 1H), 7.18 -7.12 (m, 2H), 4.32 -4.20 (m, 2H) Step 4:
To a 1,4-dioxane (74 mL) solution of tert-butyl 4-(2-(benzylamino)-2-oxo-1-phenylethyl)piperazine-1-carboxylate (S4, 14.7 g, 35.9 mmol) was added hydrogen chloride (4.0 M in 1,4-dioxane, 40. mL, 180 mmol), and the reaction mixture was stirred at rt for 12 h. The reaction mixture was then concentrated in vacuo. The material was then stirred with Et 2 O (50 mL) and filtered to afford racemic N-benzyl-2-phenyl-2-(piperazin-1-yl)acetamide hydrochloride as white amorphous solid.
This racemate was subjected to preparatory SFC purification using a (S,S) Whelk-O column (5 μm, 5 x 15 cm), eluting with 30% MeOH containing 0.2% HNEt 2 at a flowrate of 350 mL/min with diode array detection at 225 nm, to provide (R)-N-benzyl-2-phenyl-2-(piperazin-1-yl)acetamide (S5, 5.08 g, 16.4 mmol, 46% yield, >99%ee) as a white amorphous solid. Step 5:
To a CH 2 Cl 2 (5.4 mL) solution of 2-chloro-5-fluorobenzoic acid (0.283 g, 1.62 mmol) and (R)-Nbenzyl-2-phenyl-2-(piperazin-1-yl)acetamide (S5, 0.502 g, 1.62 mmol) was added triethylamine (0.34 mL, 2.4 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 1.5 mL, 2.4 mmol). The solution was stirred at rt for 16 h. Sat. aq. NaHCO 3 was added. The mixture was stirred at rt for 30 min and partitioned. The aqueous layer was washed twice with CH 2 Cl 2 . The combined organic extracts were combined, washed with brine, dried over MgSO 4 , filtered, and concentrated in vacuo. The material was absorbed onto a plug of silica gel and purified by chromatography through a Biotage Snap Ultra pre-packed silica gel column (25 g), eluting with a gradient of 10% to 70% EtOAc in heptane, to provide 14 (0.69 g, 1.5 mmol, 91 % yield) as a white amorphous solid. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.68 (t, J=6.1 Hz, 1H), 1H), 7.42 (d, J=7.0 Hz, 2H), 5H), 2H), 1H), 7.14 (d, J=7.8 Hz, 2H), 2H), 3.95 (s, 1H), 2H), 3.17 (t, J=4.9 Hz, 2H), 2.48 -2.38 (m, 2H), 2.38 -2.28 (m, 2H).
13
C NMR (101 MHz, DMSO-d 6 ) δ 169. 98, 164.04, 161.94, 159.50, 139.38, 137.40, 137.32, 136.94, 131.42, 131.34, 128.61, 128.18, 127.76, 127.01, 126.68, 124.49, 124.46, 117.64, 117.41, 115.17, 114.93, 79.15, 73.89, 73.87, 50.43, 46.09, 41.95 To a CH 2 Cl 2 (19.5 mL) solution of 2-chloro-5-fluoronicotinic acid (1.128 g, 6.43 mmol) and (R)-N-benzyl-2-phenyl-2-(piperazin-1-yl)acetamide (S5, 1.808 g, 5.84 mmol) in dichloromethane was added triethylamine (1.2 mL, 8.8 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 5.6 mL, 8.77 mmol). The solution was stirred at rt for 16 h. Sat. aq. NaHCO 3 was added. The mixture was stirred at rt for 30 min and partitioned. The aqueous layer was washed twice with CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over MgSO 4 , filtered, and concentrated in vacuo. The material was absorbed onto a plug of silica gel and purified by chromatography through a Reveleris HP 20 µm pre-packed silica gel column (40 g), eluting with a gradient of 20% to 70% EtOAc in heptane, to provide 15 (1.90 g, 4.07 mmol, 70% yield) as a white amorphous solid. To a CH 2 Cl 2 (7 mL) solution of 3,5-difluorobenzoic acid (0.333 g, 2.11 mmol) and (R)-Nbenzyl-2-phenyl-2-(piperazin-1-yl)acetamide (S5, 0.652 g, 2.11 mmol) was added triethylamine (0.44 mL, 3.2 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 2.0 ml, 3.2 mmol). The solution was stirred at rt for 16 h. Sat. aq. NaHCO 3 was added. The mixture was stirred at rt for 30 min and partitioned. The aqueous layer was washed twice with CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over MgSO 4 , filtered, and concentrated in vacuo. The material was absorbed onto a plug of silica gel and purified by chromatography through a Biotage Snap Ultra pre-packed silica gel column (25 g), eluting with a gradient of 0% to 70% EtOAc in heptane, to provide 16 (0.90 g, 2.0 mmol, 95% yield) as a white amorphous solid. To a CH 2 Cl 2 (20 mL) solution of 3-cyano-5-fluorobenzoic acid (1.584 g, 9.59 mmol) and (R)-Nbenzyl-2-phenyl-2-(piperazin-1-yl)acetamide (S5, 3.0277 g, 9.79 mmol) was added triethylamine (2.0 mL, 15 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 9.3 mL, 15 mmol). The solution was stirred at rt for 16 h. Sat. aq. NaHCO 3 was added. The mixture was stirred at rt for 30 min and partitioned. The aqueous layer was washed twice with CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over MgSO 4 , filtered, and concentrated in vacuo. The material was absorbed onto a plug of silica gel and purified by chromatography through a Reveleris HP 20 µm pre-packed silica gel column (40 g), eluting with a gradient of 20% to 80% EtOAc in heptane, to provide 17 (4.3 g, 9.4 mmol, 96% yield) as a white amorphous solid. A CH 2 Cl 2 (44 mL) solution of (R)-N-benzyl-2-phenyl-2-(piperazin-1-yl)acetamide (S5, 8.19 g, 26.5 mmol), 3-cyano-5-(trifluoromethoxy)benzoic acid (7.34 g, 31.8 mmol), and triethylamine (7.4 ml, 53 mmol) was cooled to 0 °C and then treated with propylphosphonic anhydride (50 wt% in EtOAc, 31.5 ml, 52.9 mmol). After stirring the yellow slurry 16 h while slowly warming to rt, the reaction was quenched with sat. aq. NaHCO 3 , stirred for 1 h and subsequently extracted thrice with CH 2 Cl 2 . The organic extracts were combined, filtered through a phase separator, and concentrated in vacuo. The material was absorbed onto a plug of silica gel and purified by column chromatography through a Biotage Snap Ultra column (100 g), eluting with 0% to 100% EtOAc in heptane with 10% CH 2 Cl 2 cosolvent, to provide 18 (7.5114 g, 14.38 mmol, 54% yield) as a white amorphous solid. Step 1:
To a MeCN (70 mL) slurry of 2-chloro-5-fluorobenzoic acid (3.00 g, 17.2 mmol), tert-butyl piperazine-1-carboxylate (3, 3.20 g, 17.2 mmol), and triethylamine (7.2 ml, 52 mmol) cooled in an ice water bath was added (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylaminomorpholino-carbenium hexafluorophosphate (COMU, 7.73 g, 18.1 mmol). The resulting yellow solution was stirred for 3 h while allowing the reaction to slowly warm to rt. The mixture was then concentrated in vacuo and purified by column chromatography using a Silicycle HP column (120 g), eluting with 0% to 100% EtOAc in heptane with 5% CH 2 Cl 2 cosolvent, to afford tertbutyl 4-(2-chloro-5-fluorobenzoyl)piperazine-1-carboxylate (S6, 5.53 g, 16.1 mmol, 94% yield) as a white flocculent solid. HPLC (System A) R t 1.22 min. LCMS (ESI) m/z: 365.0 (M+Na) + .
Step 2:
To a CH 2 Cl 2 (65 mL) solution of tert-butyl 4-(2-chloro-5-fluorobenzoyl)piperazine-1-carboxylate (S6, 5.53 g, 16.1 mmol) cooled in an ice water bath was added trifluoroacetic acid (8.7 mL, 110 mmol). The reaction was allowed to warm to rt while stirring for 18 h. The reaction was concentrated in vacuo and absorbed on a Biotage Isolute SCX-2 strong cation exchange column (20 g), washing with MeOH prior to eluting with 2 M NH 3 in MeOH, to afford (2-chloro-5-fluorophenyl) (piperazin-1-yl) Step 3:
To a TFE (2 mL) solution of (2-chloro-5-fluorophenyl)(piperazin-1-yl)methanone (S7, 86 mg, 0.25 mmol) was added 4-formylbenzonitrile (S8, 33 mg, 0.25 mmol) and acetic acid (17 μL, 0.30 mmol) dropwise. To this solution was added benzyl isocyanide (1, 30. μL, 0.25 mmol). The reaction was stirred 16 h at rt. The mixture was then concentrated in vacuo. The material was purified by preparative reversed-phase high-performance liquid chromatography to afford rac-19 (32.5 mg, 0.0662 mmol, 26% yield) as a white amorphous solid. This racemate was subjected to preparatory SFC purification using a (S,S) Whelk-O column (5 μm, 2 x 15 cm), eluting with 50% MeOH at a flowrate of 80 mL/min with diode array detection at 215 nm, to provide 19 (14.2 mg, >99%ee) as a white amorphous solid. 
(R)-N-Benzyl-2-(4-cyano-3-methylphenyl)-2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)acetamide (20).
To a vial charged with 4-formyl-2-methylbenzonitrile (S9, 0.051 g, 0.35 mmol) was sequentially added (2-chloro-5-fluorophenyl)(piperazin-1-yl)methanone (S7, 0.085 g, 0.350 mmol), TFE (2.8 mL), acetic acid (0.024 ml, 0.42 mmol), and benzyl isocyanide (1, 0.043 mL, 0.35 mmol). The vial was shaken for 18 h at 40 °C. The reaction was absorbed on a Biotage Isolute SCX-2 strong cation exchange column (2 g), washing with MeOH prior to eluting with 2 M NH 3 in MeOH. The filtrate was concentrated in vacuo and purified via preparatory reverse-phase purification, eluting with 10% to 30% MeCN in H 2 O containing 0.1% NH 4 OH, to afford rac-20 (0.0995 g, 0.197 mmol, 56% yield) as a white amorphous solid. A portion of this racemate (0.094 g) was subjected to preparatory SFC purification using a Chiralpak AD-H column (5 μm, 2 x 15 cm), eluting with 40% i-PrOH containing 0.2% HNEt 2 at a flowrate of 80 mL/min with diode array detection at 215 nm, to provide 20 (0.0152 g, >99%ee) as a white amorphous solid. 
(R)-N-Benzyl-2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-N-methyl-2-phenylacetamide (21).
To a CH 2 Cl 2 (60 mL) solution of tert-butyl 4-(2-methoxy-2-oxo-1-phenylethyl)piperazine-1-carboxylate (S2, 6.05 g, 18.09 mmol) was added 2,2,2-trifluoroacetic acid (34.6 mL, 452 mmol). The reaction was stirred at rt for 2 h. The reaction was then basified with 6 N NaOH and extracted with thrice with CH 2 Cl 2 . The organic extracts were combined, dried over MgSO 4 , filtered, and concentrated in vacuo to provide methyl 2-phenyl-2-(piperazin-1-yl)acetate (S10) as a yellow oil that was used without further purification. Step 2:
To a CH 2 Cl 2 (36 mL) solution of 3,5-difluorobenzoic acid (2.86 g, 18.10 mmol) and methyl 2-phenyl-2-(piperazin-1-yl)acetate (S10) from the prior step was added triethylamine (5.0 mL, 36 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 9.3 mL, 15 mmol). The solution was stirred at rt for 16 h. Sat. aq. NaHCO 3 was added. The mixture was stirred at rt for 30 min and partitioned. The aqueous layer was washed twice with CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over MgSO 4 , filtered, and concentrated in vacuo to provide methyl 2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetate (S11, 6.71 g, 17.9 mmol, 99% yield over 2 steps) as a tan amorphous solid. HPLC (System A) R t 0.92 min. LCMS (ESI) m/z:
Step 3:
A THF (70 mL)/MeOH (12 mL)/H 2 O (12 mL) solution of methyl 2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetate (S11, 6.70 g, 17.90 mmol) and lithium hydroxide (2.14 g, 89.0 mmol) was stirred at rt for 4 h. The mixture was cooled using an ice-H 2 O bath and then acidified to ca. pH 3 with 2 N HCl. The mixture was then extracted thrice with CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over MgSO 4 , filtered, and concentrated in vacuo to afford racemic 2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetic acid (rac-S12, 5.30 g, 14.7 mmol, 82% yield) as a white amorphous solid. This racemate was subjected to preparatory SFC purification using a Chiralpak AD-H column (5 μm, 2 x 25 cm), eluting with 25% MeOH at a flowrate of 70 mL/min with diode array detection at 215 nm, to provide (R)-2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetic acid (S12, 1.82 g, >99%ee). HPLC (System A) R t 1.09 min. LCMS (ESI) m/z: 361.2 (M+H) + .
Step 4:
To a CH 2 Cl 2 (1 mL) mixture of N-methyl-1-phenylmethanamine (0.024 g, 0.20 mmol), (R)-2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetic acid (S12, 0.072 g, 0.20 mmol) was sequentially added triethylamine (0.056 mL, 0.40 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 0.26 mL, 0.40 mmol). The mixture was shaken at rt for 16 h. Sat. aq. NaHCO 3 was added. The mixture was shaken at rt for 30 min and partitioned in a phase separator, and the filtrate was dried in vacuo. The material was purified via high throughput parallel purification to provide 21 (56.0 mg, 0.121 mmol, 60% yield) as a white amorphous solid. To a DMF (1 mL) mixture of (6-(trifluoromethyl)pyridin-3-yl)methanamine (0.044 g, 0.25 mmol), 2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetic acid (rac-S12, 0.080 g, 0.22 mmol) was added triethylamine (0.062 mL, 0.44 mmol) and propylphosphonic anhydride (50 wt% in DMF, 0.28 mL, 0.44 mmol). The mixture was stirred at rt for 16 h. The reaction was purified via preparatory reverse-phase purification, eluting with 5% to 95% MeCN in H 2 O using 0.1% NH 4 OH additive, to provide rac-22 (63.4 mg, 0.122 mmol, 55% yield) as a white amorphous solid. This racemate was subjected to preparatory SFC purification using a (S,S) Whelk-O column (5 μm, 2 x 15 cm), eluting with 35% MeOH containing 0.2% HNEt 2 at a flowrate of 80 mL/min with diode array detection at 254 nm, to provide 22 (21.5 mg, >99%ee) as a white amorphous solid. (R)-2-(4-(3,5-Difluorobenzoyl)piperazin-1-yl)-2-phenyl-N-(4-(trifluoromethyl)phenyl) acetamide (23).
To a DMF (0.5 mL) mixture of 4-(trifluoromethyl)aniline (0.040 g, 0.25 mmol) and 2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetic acid (rac-S12, 0.090 g, 0.25 mmol) was added triethylamine (0.070 mL, 0.50 mmol) and propylphosphonic anhydride (50 wt% in DMF, 0.32 mL, 0.50 mmol). The mixture was stirred at rt for 16 h. The reaction was then purified via high throughput parallel purification to provide rac-23 (35.7 mg, 0.0709 mmol, 28% yield) as a white amorphous solid. This racemate was subjected to preparatory SFC purification using a (S,S) Whelk-O column (5 μm, 2 x 15 cm), eluting with 30% MeOH containing 0.2% HNEt 2 at a flowrate of 80 mL/min with diode array detection at 250 nm to provide 23 (16.1 mg, >99%ee) as a white amorphous solid. To a DMF (0.5 mL) mixture of 6-(2,2,2-trifluoroethoxy)pyridin-3-amine (0.048 g, 0.25 mmol), 2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetic acid (rac-S12, 0.090 g, 0.25 mmol) was added triethylamine (0.070 mL, 0.50 mmol) and propylphosphonic anhydride (50 wt% in DMF, 0.32 mL, 0.50 mmol). The mixture was stirred at rt for 16 h. The reaction was purified via high throughput parallel purification to provide rac-24 (27.3 mg, 0.0511 mmol, 20% yield) as a white amorphous solid. This racemate was subjected to preparatory SFC purification using a (S,S) Whelk-O column (5 μm, 2 x 15 cm), eluting with 35% MeOH containing 0.2% HNEt 2 at a flowrate of 80 mL/min with diode array detection at 215 nm, to provide 24 (8.0 mg, >99%ee) as a white amorphous solid. 
(R)-N-(Cyclopropylmethyl)-2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetamide (25).
To a CH 2 Cl 2 (1 mL) mixture of cyclopropylmethanamine (0.014 g, 0.20 mmol) and (R)-2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetic acid (S12, 0.072 g, 0.20 mmol) was sequentially added triethylamine (0.056 mL, 0.40 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 0.26 mL, 0.40 mmol). The mixture was shaken at rt for 16 h. Sat. aq. NaHCO 3 was added. The mixture was shaken at rt for 30 min and partitioned in a phase separator, and the filtrate was dried in vacuo. The material was purified via high throughput parallel purification to provide 25 (14.3 mg, 0.0344 mmol, 17% yield) as a white amorphous solid. To a DMF (0.75 mL) mixture of 2-cyclopropyl-2,2-difluoroethanamine (0.047 g, 0.30 mmol), (R)-2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-2-phenylacetic acid (S12, 0.054 g, 0.15 mmol) was sequentially added triethylamine (0.042 mL, 0.30 mmol) and propylphosphonic anhydride (50 wt% in DMF, 0.19 mL, 0.30 mmol). The mixture was shaken at rt for 16 h. The material was filtered and purified via high throughput parallel purification to provide 26 (38.1 mg, 0.0822 mmol, 55% yield) as a white amorphous solid. (R)-N-Benzyl-2-(6-(2-chloro-5-fluorobenzoyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-phenylacetamide (27).
A TFE (8 mL) solution of tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (S13, 203 mg, 1.024 mmol) was treated with benzaldehyde (S14, 0.10 mL, 1.0 mmol), acetic acid (0.070 mL, 1.2 mmol), and benzyl isocyanide (1, 125 µl, 1.02 mmol). The solution was stirred for 18 h at rt. The reaction was then filtered through a Biotage Isolute SCX-2 strong cation exchange column (5 g), washing with MeOH prior to eluting with 2 M NH 3 in MeOH. The filtrate was concentrated in vacuo and purified by column chromatography through a Biotage Snap Ultra column (25 g), eluting with 0% to 100% EtOAc in heptane with 5% CH 2 Cl 2 cosolvent, to afford tert-butyl 3-(2-(benzylamino)-2-oxo-1-phenylethyl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (S15, 252.8 mg, 0.600 mmol, 59% yield) as a white amorphous solid. HPLC (System A) R t 1.05 min. LCMS (ESI) m/z: 422.2 (M+H) + .
A CH 2 Cl 2 (3 mL) solution of tert-butyl 3-(2-(benzylamino)-2-oxo-1-phenylethyl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (S15, 252.8 mg, 0.600 mmol) was treated with trifluoroacetic acid (1.5 mL, 20. mmol). The solution was stirred at rt for 1 h. The reaction was then quenched with sat. aq. NaHCO 3 until the aqueous layer pH >8. The reaction was extracted thrice with CH 2 Cl 2 . The organic extracts were passed through a phase separator, combined, and concentrated in vacuo to afford N-benzyl-2-(3,6-diazabicyclo[3.1.1] heptan-3-yl)-2-phenylacetamide (S16) as an off-white amorphous solid that was used without further purification. HPLC (System A) R t 0.83 min. LCMS (ESI) m/z: 322.2 (M+H) + .
To a CH 2 Cl 2 (1.3 mL) mixture of N-benzyl-2-(3,6-diazabicyclo[3.1.1] heptan-3-yl)-2-phenylacetamide (S16) from the previous step and 2-chloro-5-fluorobenzoic acid (160. mg, 0.917 mmol) was sequentially added triethylamine (0.21 mL, 1.5 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 0.91 mL, 1.5 mmol). The mixture was stirred at rt for 18 h. Sat. aq. NaHCO 3 was added. The mixture was shaken at rt for 1 h and then extracted thrice with CH 2 Cl 2 . The organic extracts were combined, partitioned through a phase separator, and the organic filtrate was concentrated in vacuo. The material was purified via column chromatography through a Biotage Snap Ultra column (25 g), eluting with 0% to 50% EtOAc in heptane, to provide rac-27 (201.7 mg, 0.422 mmol, 70% yield over 2 steps) as a white amorphous solid. HPLC (System A) R t 1.94 min. LCMS (ESI) m/z: 416.2 (M+H) + . This racemate was subjected to preparatory SFC purification using a (S,S) Whelk-O column (5 μm, 2 x 25 cm), eluting with 40% MeOH at a flowrate of 80 mL/min with diode array detection at 215 nm, to provide 27 (76.0 mg, >99%ee) as a white amorphous solid. Step 1:
A DMF (1.4 mL) slurry of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (S17, 299.2 mg, 1.409 mmol), potassium carbonate (234 mg, 1.69 mmol), and methyl 2-bromo-2-phenylacetate (S1, 323 mg, 1.41 mmol) was stirred for 3 d at rt. Step 2:
A THF (2.8 mL)/MeOH (1 mL)/H 2 O (1 mL) solution of tert-butyl 3-(2-methoxy-2-oxo-1-phenylethyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (S18, 498.4 mg, 1.383 mmol) was treated with lithium hydroxide monohydrate (296 mg, 7.05 mmol). The reaction was stirred for 18 h at rt. The reaction was then acidified with 2 N HCl until the pH was < 2 and then extracted four times with CH 2 Cl 2 . The organic extracts were combined, filtered through a phase separator, and concentrated in vacuo to afford 2-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-phenylacetic acid (S19, 407.0 mg, 1.175 mmol, 85 % yield) as a white amorphous solid that was used without further purification. HPLC (System A) R t 0.89 min. LCMS (ESI) m/z: 347.2 (M+H) + .
A CH 2 Cl 2 (2.0 mL) solution of 2-(8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-phenylacetic acid (S19, 407.0 mg, 1.175 mmol), benzylamine (0.14 mL, 1.29 mmol), and triethylamine (0.33 mL, 2.4 mmol) was treated with propylphosphonic anhydride (50 wt% in EtOAc, 1.4 mL, 2.4 mmol). After stirring the slurry at rt for 18 h, the reaction was quenched with sat. aq. NaHCO3, and the mixture was stirred for 1 h and subsequently extracted thrice with CH 2 Cl 2 . The organic extracts were combined, filtered through a phase separator, and concentrated in vacuo. The material was purified via column chromatography through a Biotage Snap Ultra column (100 g), eluting with 0% to 100% EtOAc in heptane with 5% CH 2 Cl 2 cosolvent, to afford tert-butyl 3-(2-(benzylamino)-2-oxo-1-phenylethyl Step 4:
A CH 2 Cl 2 (5 mL) solution of tert-butyl 3-(2-(benzylamino)-2-oxo-1-phenylethyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (S20, 384.6 mg, 0.883 mmol) was treated with trifluoroacetic acid (1.7 mL, 23 mmol). After stirring for 1 h at rt, sat. aq. NaHCO 3 was added until pH > 7. The mixture was extracted thrice with CH 2 Cl 2 . The organic extracts were filtered through a phase separator, combined, and concentrated in vacuo to afford N-benzyl-2-(3,8-diazabicyclo[3.2 .1]octan-3-yl)-2-phenylacetamide (S21) as an off-white amorphous solid that was used without further purification. HPLC (System A) R t 0.87 min. LCMS (ESI) m/z: 336.2 (M+H) + .
Step 5:
A CH 2 Cl 2 (1.0 mL) solution of N-benzyl-2-(3,8-diazabicyclo[3.2.1] octan-3-yl)-2-phenylacetamide (S21, 0.200 g, 0.596 mmol), 2-chloro-5-fluorobenzoic acid (125 mg, 0.715 mmol), and triethylamine (0.17 mL, 1.2 mmol) was treated with propylphosphonic anhydride (50 wt% in EtOAc, 0.71 mL, 1.2 mmol). After stirring the solution at rt for 18 h, the reaction was quenched with sat. aq. NaHCO 3 , and the mixture was stirred for 1 h and subsequently extracted thrice with CH 2 Cl 2 . The organic extracts were combined, filtered through a phase separator, and concentrated in vacuo. The material was purified via column chromatography through a Biotage Snap Ultra column (100 g), eluting with 0% to 50% EtOAc in heptane, to afford rac-28 (144.7 mg, 0.294 mmol, 33% yield over 2 steps) as a white amorphous solid. This racemate was subjected to preparatory SFC purification using a (S,S) Whelk-O column (5 μm, 2 x 15 cm), eluting with 55% MeOH at a flowrate of 80 mL/min with diode array detection at 220 nm to provide 28 (41.4 mg, >99%ee) as a white amorphous solid. Step 1:
A CH 2 Cl 2 (50 mL) solution of 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-phenylacetic acid (S3, 9.87 g, 30.8 mmol), 6-(2,2,2-trifluoroethoxy)pyridin-3-amine (5.89 g, 30.8 mmol), and triethylamine (8.6 mL, 62 mmol) was cooled to 0 °C and then treated with propylphosphonic anhydride (50 wt% in EtOAc, 37 mL, 61.6 mmol) portionwise over 1 min. After stirring the solution at rt for 18 h while allowing to slowly warm to rt, the reaction was quenched with sat. aq. NaHCO 3 , and the mixture was stirred for 1 h and subsequently extracted thrice with CH 2 Cl 2 . The organic extracts were combined, filtered through a phase separator, and concentrated in vacuo. The material was purified via column chromatography through a Biotage Snap Ultra column (100 g), eluting 0% to 100% EtOAc in heptane with 5% CH 2 Cl 2 cosolvent, to afford tertbutyl 4-(2-oxo-1-phenyl-2-((6-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)ethyl)piperazine-1-carboxylate (S22, 12.51 g, 25.3 mmol, 82 % yield) as a sepia amorphous solid. HPLC (System A) R t 1.11 min. LCMS (ESI) m/z: 495.2 (M+H) + .
A CH 2 Cl 2 (25 mL) solution of tert-butyl 4-(2-oxo-1-phenyl-2-((6-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)ethyl)piperazine-1-carboxylate (S22, 12.51 g, 25.3 mmol) was treated with hydrogen chloride (4.0 M in dioxane, 28.4 ml, 114 mmol). After stirring solution for 30 min at rt, sat. aq. NaHCO 3 was added until pH > 7. The mixture was extracted thrice with CH 2 Cl 2 . The organic extracts were combined, filtered through a phase separator, and concentrated in vacuo to afford racemic 2-phenyl-2-(piperazin-1-yl)-N-(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acetamide hydrochloride (rac-S23·HCl) as a brown amorphous solid. This racemate was subjected to preparatory SFC purification using a Chiralpak AS-H column (5 μm, 5 x 15 cm), eluting with 20% i-PrOH at a flowrate of 350 mL/min with diode array detection at 215 nm to provide (R)-2-phenyl-2-(piperazin-1-yl)-N-(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acetamide (S23, 6.75 g, 17.1 mmol, 15% yield, >99%ee) as a brown amorphous solid. HPLC (System A) R t 0.95 min.
LCMS (ESI) m/z: 395.2 (M+H) + .
A CH 2 Cl 2 (4.2 mL) solution of (R)-2-phenyl-2-(piperazin-1-yl)-N-(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acetamide (S23, 1.00 g, 2.54 mmol), 2-chloro-5-fluoronicotinic acid (0.534 g, 3.04 mmol), and triethylamine (0.71 ml, 5.1 mmol) was treated with propylphosphonic anhydride (50 wt% in EtOAc, 3.0 mL, 5.1 mmol). After stirring the slurry at rt for 18 h, the reaction was quenched with sat. aq. NaHCO 3 , and the mixture was stirred for 1 h and subsequently extracted thrice with CH 2 Cl 2 . The organic extracts were combined, filtered through a phase separator, and concentrated in vacuo. The material was purified via column chromatography through a Biotage Snap Ultra column (50 g), eluting 0% to 100% EtOAc in heptane with 5% CH 2 Cl 2 cosolvent), to afford 29 (0.6982 g, 1.265 mmol, 50% yield) as a white amorphous solid. 
(R)-2-(4-Cyanophenyl)-2-(4-(3,5-difluorobenzoyl)piperazin-1-yl)-N-(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acetamide (30).
To a CCl 4 (2 L) solution of methyl 2-(4-cyanophenyl)acetate (S24, 200. g, 1.14 mol) was added N-bromosuccinimide (224 g, 1.25 mol) under N 2 atmosphere. Azobisisobutyronitrile (9.37 g, 57.1 mmol) was added to the reaction mixture, and the reaction mixture was heated at 85 °C for 16 h. The reaction mixture was then cooled to rt, filtered through celite, washed twice with hexane, and concentrated in vacuo. The material was absorbed onto a plug of silica gel and purified by column chromatography through a Redi-Sep pre-packed silica gel column (330 g), eluting 0% to 5% EtOAc in hexane, to provide methyl 2-bromo-2-(4-cyanophenyl)acetate (S25, 110. g, 433 mmol, 38% yield) as an orange oil. Step 2:
To a DMF (3 L) solution of tert-butyl piperazine-1-carboxylate (3, 55 g, 240 mmol) was added potassium carbonate (44.5 g, 325 mmol) and methyl 2-bromo-2-(4-cyanophenyl)acetate (S25, 60. g, 240 mmol). The reaction mixture was stirred at rt for 12 h. The reaction was then filtered through a bed of celite, and the filtrate was concentrated in vacuo. The material was purified by column chromatography through a Redi-Sep pre-packed silica gel column (330 g), eluting 0% to 10% EtOAc in hexane, to provide tert-butyl 4-(1-(4-cyanophenyl)-2-methoxy-2-oxoethyl)piperazine-1-carboxylate (S26, 40. g, 110 mmol, 38% yield) as a white amorphous solid. Step 3:
To a THF (400 mL)/H 2 O (200 mL) solution of tert-butyl 4-(1-(4-cyanophenyl)-2-methoxy-2-oxoethyl)piperazine-1-carboxylate (S26, 40. g, 110 mmol) was added lithium hydroxide (13.33 g, 557.1 mmol), and the reaction mixture was stirred at rt for 2 h. Volatiles were then removed in vacuo. The concentrate was cooled to 0 °C and acidified with HOAc to adjust to about pH 6. The aqueous layer was extracted twice with CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo to afford 2-(4-(tertbutoxycarbonyl)piperazin-1-yl)-2-(4-cyanophenyl)acetic acid (S27, 30. g, 87 mmol, 78% yield) as a white amorphous solid. Step 4:
To a CH 2 Cl 2 (160 mL) solution of 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-(4-cyanophenyl)acetic acid (S27, 15.82 g, 45.8 mmol) was added 6-(2,2,2-trifluoroethoxy)pyridin-3-amine (8.0 g, 42 mmol). Triethylamine (11.6 mL, 83.2 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 26.5 g, 83.2 mmol) was added to the reaction mixture after cooling to 0 °C. The reaction mixture was stirred at rt for 16 h. The reaction mixture was then quenched with sat. aq. NaHCO 3 and extracted thrice with CH 2 Cl 2 . The organic extracts were combined, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The material was purified by column chromatography through a Redi-Sep pre-packed silica gel column (120 g), eluting 0% to 50% EtOAc in hexane, to provide tert-butyl 4-(2-oxo-1-phenyl-2-((6-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)ethyl)piperazine-1-carboxylate (S28, 17 g, 34 mmol, 79% yield) as a white amorphous solid. Step 5:
To a CH 2 Cl 2 (340 mL) solution of tert-butyl 4-(2-oxo-1-phenyl-2-((6-(2,2,2-trifluoroethoxy)pyridin-3-yl)amino)ethyl)piperazine-1-carboxylate (S28, 17 g, 33 mmol) was added trifluoroacetic acid (12.6 mL, 164 mmol). The reaction mixture was stirred at rt for 2 h. The reaction mixture was then concentrated in vacuo. The residue was dissolved in CH 2 Cl 2 and basified with 20% NaHCO 3 (aq.) solution to adjust the pH to about 9. The organic layer was separated, washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo to afford racemic 2-(4-cyanophenyl)-2-(piperazin-1-yl)-N-(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acetamide (rac-S29) as an off-white amorphous solid. This racemate was subjected to preparatory SFC purification using a YMC Amylose SA column (5 μm, 3 x 25 cm), eluting with 30% 20 mM NH 3 in MeOH at a flowrate of 120 mL/min with diode array detection at 230 nm, to provide (R)-2-(4-cyanophenyl)-2-(piperazin-1-yl)-N-(6-(2,2,2-trifluoroethoxy)pyridin-3- Step 6:
A DMF (0.45 mL) solution of (R)-2-(4-cyanophenyl)-2-(piperazin-1-yl)-N-(6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acetamide (S29, 75 mg, 0.18 mmol) and 3,5-difluorobenzoic acid (34 mg, 0.21 mmol) was treated with a DMF (0.9 mL 
(R)-2-(4-Cyanophenyl)-N-(cyclopropylmethyl)-2-(8-(3,5-difluorobenzoyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)acetamide (31).
To a THF (250 mL)/MeOH (250 mL)/H 2 O (250 mL) solution of methyl 2-bromo-2-(4-cyanophenyl)acetate (S25, 50. g, 200 mmol) was added lithium hydroxide (4.71 g, 197 mmol) after cooling to 0 °C. The reaction mixture was stirred at 0 °C for 2 min. The reaction mixture was then acidified to about pH 2 with 1.5 N HCl (aq.) and extracted twice with CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo to afford 2-bromo-2-(4-cyanophenyl)acetic acid (S30, 45 g, 190 mmol, 95% yield) as a colourless syrup. Step 2:
To a CH 2 Cl 2 (200 mL) solution of 2-bromo-2-(4-cyanophenyl)acetic acid (S30, 47.3 g, 197 mmol), cyclopropylmethanamine (14 g, 200 mmol), and triethylamine (55 mL, 390 mmol) was added propylphosphonic anhydride (50 wt% in EtOAc, 125 g, 394 mmol) after cooling to 0 °C. The reaction mixture was stirred for 16 h while allowing to slowly warm to rt. The reaction mixture was then quenched with sat. aq. NaHCO 3 and extracted twice with CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The material was purified by column chromatography through a Redi-Sep pre-packed silica gel column (330 g), eluting 0% to 20% EtOAc in hexane, to provide 2-bromo-2-(4-cyanophenyl)-N-(cyclopropylmethyl)acetamide (S31, 26 g, 89 mmol, 45% yield) as an off-white amorphous solid. Step 3:
A DMF (12 mL) slurry of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (S17, 2.5 g, 11.8 mmol), potassium carbonate (3.58 g, 25.9 mmol), and 2-bromo-2-(4-cyanophenyl)-N- Step 5:
A DMF (0.45 mL) solution of (R)-2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(4-cyanophenyl)-N-(cyclopropylmethyl)acetamide (S33, 57 mg, 0.18 mmol) and 3,5-difluorobenzoic acid (34 mg, 0.21 mmol) was treated with a DMF (0.45 mL) solution of 1-hydroxybenzotriazole hydrate (35 mg, 0.23 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (44 mg, 0.23 mmol), and Hünig's base (91 µL, 0.53 mmol). The reaction was shaken at rt for 18 h and then purified via high throughput parallel purification to provide 31 (47.6 mg, 0.103 mmol, 59% yield) as a white amorphous solid. 69, 163.94, 163.91, 163.31, 143.24, 132.14, 129.39, 118.71, 110.63, 110.56, 110.46, 110.37, 105.46, 105.21, 79.15, 72.68, 56.63, 51.94, 42.64, 10.70, 3 .04, 2.92. 62, 168.60, 159.62, 159.60, 143.19, 132.14, 132.10, 129.38, 119.50, 118.70, 117.98, 117.94, 110.46, 110.43, 79.15, 72.57, 72.53, 56.62, 56.36, 56.32, 56.19, 55.22, 54.90, 51.73, 51.67, 42.66, 42.64, 27.88, 27.71, 26.81, 26.59, 10.71, 10.67, 3.04, 2.92 . Step 1:
To a CH 2 Cl 2 (6.4 mL) solution of 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-phenylacetic acid (S3, 0.618 g, 1.93 mmol) was added 2-cyclopropyl-2,2-difluoroethanamine hydrochloride (0.304 g, 1.93 mmol). Triethylamine (0.94 mL, 6.8 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 2.5 mL, 3.9 mmol) was added to the reaction mixture. The reaction mixture was stirred at rt for 16 h. The reaction mixture was then quenched with sat. aq. NaHCO 3 , stirred for 30 min, and extracted twice with CH 2 Cl 2 . The organic extracts were combined, dried over MgSO 4 , filtered, and concentrated in vacuo to provide tert-butyl 4-(2-((2-cyclopropyl-2,2-difluoroethyl)amino)-2-oxo-1-phenylethyl)piperazine-1-carboxylate (S34) as an off-white amorphous solid that was used without further purification. HPLC (System A) R t 1.00 min.
A CH 2 Cl 2 (5 mL) of 4-(2-((2-cyclopropyl-2,2-difluoroethyl)amino)-2-oxo-1-phenylethyl)piperazine-1-carboxylate (S34) from the previous step was treated with trifluoroacetic acid (2.9 ml, 39 mmol). The mixture was stirred at rt for 2 h. The mixture was basified with 6 N NaOH until pH 9. The mixture was then extracted thrice with CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over MgSO 4 , filtered, and concentrated in vacuo to provide racemic N-(2-cyclopropyl-2,2-difluoroethyl)-2-phenyl-2-(piperazin-1-yl)acetamide (rac-S35, 0.555 g, 1.72 mmol, 89% yield over 2 steps) as an off-white amorphous solid. This racemate was subjected to preparatory SFC purification using a Chiralpak AD-H column (5 μm, 2 x 25 cm), eluting with 25% MeOH containing 0.2% HNEt 2 at a flowrate of 60 mL/min with diode array detection at 215 nm to provide (R)-N-(2-cyclopropyl-2,2-difluoroethyl)-2-phenyl-2-(piperazin-1-yl)acetamide (S35, 191 mg, >99%ee). HPLC (System A) R t 0.79 min. LCMS (ESI) m/z: 324.2 (M+H) + .
To a DMF (0.5 mL) solution of (R)-N-(2-cyclopropyl-2,2-difluoroethyl)-2-phenyl-2-(piperazin-1-yl)acetamide (S35, 0.047 g, 0.15 mmol) was added 3-cyano-5-fluorobenzoic acid (0.048 g, 0.291 mmol), triethylamine (0.041 mL, 0.291 mmol), and propylphosphonic anhydride (50 wt% in DMF, 0.19 mL, 0.291 mmol). The reaction mixture was stirred at rt for 16 h and then purified via high throughput parallel purification to provide 33 (51.6 mg, 0.110 mmol, 73% yield) as a white amorphous solid. 41, 165.49, 165.47, 162.61, 160.14, 139.53, 139.45, 136.74, 128.63, 128.20, 127.82, 127.09, 127.06, 122.09, 120.41, 120.16, 119.52, 119.50, 119.30, 117.16, 117.13, 113.30, 113.20, 79.15, 73.58, 43.02, 13.64, 0.77. Step 1:
To a CH 2 Cl 2 (800 mL) solution of tert-butyl 4-(1-(4-cyanophenyl)-2-methoxy-2-oxoethyl)piperazine-1-carboxylate (S26, 80.0 g, 223 mmol) was added trifluoroacetic acid (86.0 mL, 1.12 mol). The reaction mixture was stirred at rt for 2 h. The reaction mixture was then concentrated in vacuo. The material was dissolved in H 2 O and washed twice with MTBE. The aqueous layer was basified with 20% NaHCO 3 (aq.) to adjust to about pH 9 and then extracted twice with 10% MeOH in CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo to afford methyl 2-(4-cyanophenyl)-2-(piperazin-1-yl)acetate (S36, 50.0 g, 193 Step 2:
To a CH 2 Cl 2 (300 mL) solution of methyl 2-(4-cyanophenyl)-2-(piperazin-1-yl)acetate (S36, 20.0 g, 77.0 mmol) was added 2-chloro-5-fluorobenzoic acid (8.0 g, 77 mmol). Triethylamine (21.5 mL, 154 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 49.1 g, 154 mmol) was added to the reaction mixture after cooling to 0 °C. The reaction mixture was then stirred for 16 h while slowly warming to rt. The reaction mixture was then quenched with sat. aq. NaHCO 3 solution and was extracted twice with CH 2 Cl 2 . The organic extracts were combined, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The material was purified by column chromatography through a Redi-Sep pre-packed silica gel column (120 g), eluting 0% to 50% EtOAc in hexane, to provide methyl 2-(4-(2-chloro-5-fluorobenzoyl)piperazin-1-yl)-2-(4-cyanophenyl)acetate (S37, 20.0 g, 48.1 mmol, 62% yield) as a white amorphous solid. Step 3 :
To a THF (100 mL)/MeOH (100 mL)/H 2 O (200 mL) solution of methyl 2-(4-(2-chloro-5-fluorobenzoyl)piperazin-1-yl)-2-(4-cyanophenyl)acetate (S37, 20.0 g, 48.1 mmol) was added lithium hydroxide (5.76 g, 240 mmol), and the reaction mixture was stirred at rt for 2 h. Volatiles were then removed in vacuo. The concentrate was cooled to 0 °C and acidified with 1.5 N HCl to about pH 6. The aqueous layer was then extracted thrice with CH 2 Cl 2 . The organic extracts were combined, washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo to afford racemic 2-(4-(2-chloro-5-fluorobenzoyl)piperazin-1-yl)-2-(4-cyanophenyl)acetic acid (rac-S38, 15.0 g, 37.3 mmol, 78% yield) as a white amorphous solid. This racemate was subjected to preparatory SFC purification using a Chiralpak AD-H column (5 μm, 3 x 25 cm), eluting with 30% MeOH containing 0.5% HNEt 2 at a flowrate of 120 mL/min with diode array detection at 230 nm, to provide (R)-2-(4-(2-chloro-5-fluorobenzoyl)piperazin-1-yl)-2-(4-cyanophenyl)acetic acid (S38, 4.11 g, 96.7%ee) as a white amorphous solid. Step 4:
To a CH 2 Cl 2 (0.6 mL) mixture of 2-cyclopropyl-2,2-difluoroethanamine (0.035 g, 0.25 mmol) and (R)-2-(4-(2-chloro-5-fluorobenzoyl)piperazin-1-yl)-2-(4-cyanophenyl)acetic acid (S38, 0.050 g, 0.12 mmol) was added triethylamine (0.035 mL, 0.25 mmol) and propylphosphonic anhydride (50 wt% in EtOAc, 0.16 ml, 0.25 mmol). The mixture was shaken for 16 h at rt. The mixture was filtered and purified via high throughput parallel purification to provide 34 (36.1 mg, 0.0715 mmol, 60% yield) as a white amorphous solid. 35, 164.05, 161.95, 159.50, 142.39, 137.33, 137.26, 132.16, 131.44, 131.36, 129.56, 124.48, 124.45, 122.00, 118.67, 117.68, 117.45, 115.19, 114.94, 110.60, 72.72, 50.53, 50.38, 50.01, 49.80, 46.07, 43.38, 43.08, 41.05, 13.92, 13.64, 13.37, 0.82. 19 F NMR ( Chiral SFC spectra of rac-14, 14 (peak 1), and its enantiomer (peak 2): Chiral SFC spectra of S35 (peak 1, penultimate precursor to 33), its enantiomer (peak 2), and rac-S35. 
